PMC:7362084 / 323-490 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T2","span":{"begin":17,"end":25},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":". Currently, the antibody responses against SARS‐CoV‐2 remains largely unknown. We herein estimated the longevity of specific antibodies against SARS‐CoV‐2, and report"}

{"project":"LitCovid-PubTator","denotations":[{"id":"14","span":{"begin":44,"end":54},"obj":"Species"},{"id":"15","span":{"begin":145,"end":155},"obj":"Species"}],"attributes":[{"id":"A14","pred":"tao:has_database_id","subj":"14","obj":"Tax:2697049"},{"id":"A15","pred":"tao:has_database_id","subj":"15","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":". Currently, the antibody responses against SARS‐CoV‐2 remains largely unknown. We herein estimated the longevity of specific antibodies against SARS‐CoV‐2, and report"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T8","span":{"begin":44,"end":48},"obj":"Disease"},{"id":"T9","span":{"begin":145,"end":149},"obj":"Disease"}],"attributes":[{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":". Currently, the antibody responses against SARS‐CoV‐2 remains largely unknown. We herein estimated the longevity of specific antibodies against SARS‐CoV‐2, and report"}

{"project":"LitCovid-sentences","denotations":[{"id":"T6","span":{"begin":2,"end":79},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":". Currently, the antibody responses against SARS‐CoV‐2 remains largely unknown. We herein estimated the longevity of specific antibodies against SARS‐CoV‐2, and report"}